| Literature DB >> 35345822 |
Yurong Xiong1,2, Yun Yu1,2, Jianduan Cheng3, Wei Zhou2,4, Huihui Bao1,2,4, Xiaoshu Cheng1,2,4.
Abstract
Objective: This study aimed to assess the associations of sleep duration, midday napping and the risk of atrial fibrillation (AF) in patients with hypertension.Entities:
Keywords: atrial fibrillation; hypertension; midday napping; sleep medicine
Year: 2022 PMID: 35345822 PMCID: PMC8957307 DOI: 10.2147/CLEP.S351045
Source DB: PubMed Journal: Clin Epidemiol ISSN: 1179-1349 Impact factor: 4.790
Baseline Characteristics of the Study Participants According to Sleep Duration and Midday Napping
| Sleep Duration, Hours/Night | Midday Napping | ||||
|---|---|---|---|---|---|
| ≤5 | 6 ≥ ≤ 8 | ≥9 | No | Yes | |
| Number (%) | 496 (4.3) | 5872 (51.0) | 5156 (44.7) | 5400 (46.9) | 6124 (53.1) |
| Males, n (%) | 198 (39.9) | 2648 (45.1) | 2696 (52.3) | 2258 (41.8) | 3284 (53.6) |
| Age, y | 66.3 ± 9.0 | 62.8 ± 9.6 | 65.2 ± 9.8 | 63.8 ± 9.9 | 64.3 ± 9.6 |
| BMI, kg/m2 | 23.2 ± 3.5 | 23.7 ± 3.6 | 23.3 ± 3.5 | 23.4 ± 3.5 | 23.6 ± 3.5 |
| Physical activity, n (%) | |||||
| Mild | 299 (60.3) | 3256 (55.4) | 2959 (57.4) | 3040 (56.3) | 3474 (56.7) |
| Moderate | 97 (19.6) | 1412 (24.0) | 1132 (22.0) | 1236 (22.9) | 1405 (22.9) |
| Vigorous | 100 (20.2) | 1204 (20.5) | 1065 (20.7) | 1124 (20.8) | 1245 (20.3) |
| Smoking, n (%) | 115 (23.2) | 1524 (26.0) | 1424 (27.6) | 1291 (23.9) | 1772 (28.9) |
| Drinking, n (%) | 89 (17.9) | 1197 (20.4) | 1152 (22.3) | 1000 (18.5) | 1438 (23.5) |
| Duration of hypertension, y | 6.0 (3.0–10.0) | 6.0 (2.0–10.0) | 6.0 (3.0–10.0) | 5.5 (2.0–9.0) | 6.0 (3.0–10.0) |
| SBP, mmHg | 147.7 ± 17.1 | 146.5 ± 17.4 | 147.7 ± 17.9 | 147.4 ± 17.6 | 146.8 ± 17.6 |
| DBP, mmHg | 88.4 ± 11.0 | 88.9 ± 10.6 | 88.4 ± 11.2 | 88.8 ± 10.9 | 88.5 ± 10.8 |
| Stroke, n (%) | 40 (8.1) | 393 (6.7) | 430 (8.3) | 375 (6.9) | 488 (8.0) |
| Diabetes mellitus, n (%) | 89 (17.9) | 1046 (17.8) | 994 (19.3) | 915 (16.9) | 1214 (19.8) |
| Hyperlipidemia, n (%) | 94 (19.0) | 1089 (18.5) | 816 (15.8) | 853 (15.8) | 1146 (18.7) |
| CHD, n (%) | 49 (9.9) | 323 (5.5) | 317 (6.1) | 333 (6.2) | 356 (5.8) |
| Antihypertensive agents, n (%) | 301 (60.7) | 3625 (61.7) | 3236 (62.8) | 3315 (61.4) | 3847 (62.8) |
| Antidiabetes agents, n (%) | 22 (4.4) | 276 (4.7) | 269 (5.2) | 229 (4.2) | 338 (5.5) |
| Lipid-lowering agents, n (%) | 17 (3.4) | 195 (3.3) | 205 (4.0) | 181 (3.4) | 236 (3.9) |
| eGFR, mL/min/1.73 m2 | 83.5 ± 19.5 | 87.4 ± 18.9 | 84.2 ± 20.5 | 86.2 ± 19.8 | 85.4 ± 19.7 |
| FPG, mmol/L | 6.1 ± 1.4 | 6.1 ± 1.5 | 6.2 ± 1.6 | 6.1 ± 1.4 | 6.2 ± 1.7 |
| TG, mmol/L | 1.4 (1.0–2.0) | 1.5 (1.1–2.2) | 1.4 (1.0–2.1) | 1.5 (1.0–2.1) | 1.5 (1.0–2.2) |
| HDL-C, mmol/L | 1.6 ± 0.4 | 1.5 ± 0.4 | 1.5 ± 0.4 | 1.5 ± 0.4 | 1.5 ± 0.4 |
| LDL-C, mmol/L | 2.9 ± 0.7 | 3.0 ± 0.8 | 2.9 ± 0.8 | 2.9 ± 0.8 | 2.9 ± 0.8 |
| Sleep quality, n (%) | |||||
| Good | 41 (8.3) | 3034 (51.7) | 3628 (70.4) | 334 (6.2) | 162 (2.6) |
| Fair | 41 (8.3) | 1455 (24.8) | 814 (15.8) | 3339 (61.8) | 2533 (41.4) |
| Poor | 414 (83.5) | 1383 (23.6) | 714 (13.8) | 1727 (32.0) | 3429 (56.0) |
| Snoring status, n (%) | |||||
| No | 312 (62.9) | 3201 (54.5) | 2819 (54.7) | 3119 (57.8) | 3213 (52.5) |
| Sometimes | 129 (26.0) | 2001 (34.1) | 1709 (33.1) | 1667 (30.9) | 2172 (35.5) |
| Frequently | 55 (11.1) | 670 (11.4) | 628 (12.2) | 614 (11.4) | 739 (12.1) |
Association of Sleep Duration and Midday Napping with Atrial Fibrillation
| N | Events | OR for Prevalent Atrial Fibrillation | ||||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | |||
| Sleep duration (hours/night) | ||||||
| ≤5 | 460 | 35 | 2.65 (1.85, 3.82) | 2.22 (1.54, 3.21) | 1.95 (1.32, 2.87) | 1.95 (1.28, 2.95) |
| 6 ≥ ≤ 8 | 5668 | 157 | 1.00 | 1.00 | 1.00 | 1.00 |
| ≥9 | 4854 | 146 | 1.10 (0.89, 1.37) | 0.95 (0.76, 1.18) | 0.95 (0.76, 1.19) | 0.89 (0.71, 1.12) |
| Midday napping | ||||||
| No | 5128 | 141 | 1.00 | 1.00 | 1.00 | 1.00 |
| Yes | 5854 | 197 | 1.19 (0.97, 1.46) | 1.18 (0.96, 1.46) | 1.28 (1.03, 1.48) | 1.28 (1.03, 1.60) |
Notes: Model 1: crude model. Model 2: adjusted for age, sex, BMI, physical activity, smoking, drinking. Model 3: adjusted for age, sex, BMI, physical activity, smoking, drinking, SBP, DBP, duration of hypertension, diabetes mellitus, hyperlipidemia, CHD, antihypertensive agents, antidiabetes agents, lipid-lowering agents, FPG, TG, HDL-C, LDL-C, and eGFR. Model 4: adjusted for age, sex, BMI, physical activity, smoking, drinking, SBP, DBP, duration of hypertension, diabetes mellitus, hyperlipidemia, CHD, antihypertensive agents, antidiabetes agents, lipid-lowering agents, FPG, TG, HDL-C, LDL-C, eGFR, snoring status, sleep duration, sleep quality and midday napping. Each group adjusted for the other covariates except itself.
Figure 1Joint effects of sleep duration and midday napping on incident AF risk. Each subgroup analysis adjusted, if not stratified, for age, sex, BMI, physical activity, smoking, drinking, SBP, DBP, duration of hypertension, diabetes mellitus, hyperlipidemia, CHD, antihypertensive agents, antidiabetes agents, lipid-lowering agents, FPG, TG, HDL-C, LDL-C, eGFR, snoring status and sleep quality (*P <0.05).
Figure 2Subgroup analyses of the effect of sleep duration on incident AF risk. Each subgroup analysis adjusted, if not stratified, for age, sex, BMI, physical activity, smoking, drinking, SBP, DBP, duration of hypertension, diabetes mellitus, hyperlipidemia, CHD, antihypertensive agents, antidiabetes agents, lipid-lowering agents, FPG, TG, HDL-C, LDL-C, eGFR, snoring status, sleep quality and midday napping.
Figure 3Subgroup analyses of the effect of midday napping on incident AF risk. Each subgroup analysis adjusted, if not stratified, for age, sex, BMI, physical activity, smoking, drinking, SBP, DBP, duration of hypertension, diabetes mellitus, hyperlipidemia, CHD, antihypertensive agents, antidiabetes agents, lipid-lowering agents, FPG, TG, HDL-C, LDL-C, eGFR, snoring status and sleep duration.